We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Killer immunoglobulin‐like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment‐free remission.
- Authors
Dumas, Pierre‐Yves; Bérard, Emilie; Bréal, Claire; Dulucq, Stéphanie; Réa, Delphine; Nicolini, Franck; Forcade, Edouard; Dufossée, Melody; Pasquet, Jean‐Max; Turcq, Béatrice; Bidet, Audrey; Milpied, Noel; Déchanet‐Merville, Julie; Lafarge, Xavier; Etienne, Gabriel; Mahon, François‐Xavier
- Abstract
Background: Natural Killer (NK) cells are innate lymphoid cells that can be cytotoxic toward a large panel of solid tumors and hematological malignancies including chronic myeloid leukemia (CML). Such a cytotoxicity depends on various receptors. Killer immunoglobulin‐like receptors (KIR) belong to these receptors and are involved in maturation process, then in the activation abilities of NK cells. Methods: We investigated the prognostic impact of the KIR2DL5B genotype in 240 CML patients included in two clinical trials investigating tyrosine kinase inhibitors (TKI) discontinuation: STIM and STIM2. Results: After adjustment for standard risk factors in CML, we found that the inhibitory receptor KIR2DL5B‐positive genotype was independently related to a delayed second deep molecular remission (HR 0.54, 95% CI [0.32‐0.91], P = 0.02) after TKI rechallenge but not to time to first deep molecular remission or treatment‐free remission rates. Conclusion: These results suggest that KIR2DL5B could carry a role in lymphocyte‐mediated control of leukemic residual disease control in patient with CML relapse.
- Subjects
CHRONIC myeloid leukemia; INNATE lymphoid cells; GENOTYPES; HEMATOLOGIC malignancies; KILLER cells
- Publication
Cancer Medicine, 2019, Vol 8, Issue 11, p4976
- ISSN
2045-7634
- Publication type
Article
- DOI
10.1002/cam4.2371